Unknown

Dataset Information

0

Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).


ABSTRACT:

Background

Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function. We have therefore re-evaluated the clinical effect of combination therapy (salmeterol plus fluticasone) in moderate-to-severe COPD, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI) and trial data from Towards a Revolution in COPD Health (TORCH).

Methods

Of the 6112 TORCH participants, 5688 (93.1%) had GLI-based moderate-to-severe COPD (mean age 64.8 years). The primary outcome was all-cause mortality and the primary comparison was combination therapy vs. placebo. Secondary outcomes included COPD and cardiovascular (CV) mortality and pneumonia. A modified intention-to-treat analysis evaluated differences in time-to-event over a three-year period, using Cox proportional hazards models with statistical significance at p < 0.010 (acknowledging repeated significance testing).

Results

Relative to placebo, combination therapy yielded a statistically non-significant reduction in all-cause mortality-adjusted hazard ratio [adjHR] 0.78 (95% confidence interval [CI]: 0.64, 0.95), p = 0.012. Relative to placebo, combination therapy also yielded statistically non-significant reductions in COPD and CV mortality-adjHR 0.75 (95% CI: 0.55, 1.02), p = 0.068 and adjHR 0.76 (95% CI: 0.53, 1.09), p = 0.135, respectively. In contrast, combination therapy yielded a statistically significant increased risk of pneumonia, relative to placebo-adjHR 1.80 (95% CI: 1.46, 2.21), p < 0.001.

Conclusion

In GLI-based moderate-to-severe COPD, combination therapy yields a statistically significant increased risk of pneumonia but the reductions in mortality are not statistically significant, although could potentially be clinically meaningful.

SUBMITTER: Vaz Fragoso CA 

PROVIDER: S-EPMC6519718 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD).

Vaz Fragoso Carlos A CA   Gill Thomas M TM   Leo-Summers Linda S LS   Van Ness Peter H PH  

Respiratory medicine 20190329


<h4>Background</h4>Clinical trials of COPD pharmacotherapy typically involve aging populations with moderate-to-severe COPD, but the latter is often diagnosed by spirometric criteria that are not age-appropriate across the continuum of lung function. We have therefore re-evaluated the clinical effect of combination therapy (salmeterol plus fluticasone) in moderate-to-severe COPD, using more age-appropriate spirometric criteria from the Global Lung Function Initiative (GLI) and trial data from To  ...[more]

Similar Datasets

| PRJNA647843 | ENA
2016-05-25 | GSE77344 | GEO
| PRJEB46960 | ENA
| S-EPMC3651866 | biostudies-literature
| S-EPMC8504989 | biostudies-literature
2008-05-31 | GSE8581 | GEO
2022-10-17 | PXD035120 | Pride
2003-07-16 | GSE475 | GEO
| S-EPMC5732734 | biostudies-literature